PRQR — ProQR Therapeutics NV Cashflow Statement
0.000.00%
- $150.38m
- $59.57m
- €9.53m
Annual cashflow statement for ProQR Therapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -56.7 | -46.6 | -61.7 | -64.9 | -27.7 |
Depreciation | |||||
Non-Cash Items | 8.32 | 3.32 | 10.7 | 3.04 | -4.07 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 2.4 | -6.12 | 22.6 | -9.18 | 50.8 |
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -44 | -47.1 | -26 | -68.5 | 21.5 |
Capital Expenditures | -0.58 | -0.924 | -0.484 | -0.708 | -1.37 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | 0.059 | 0.006 | 5.65 |
Sale of Fixed Assets | |||||
Sale of Intangible Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.58 | -0.924 | -0.425 | -0.702 | 4.28 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 50.2 | 14.5 | 137 | -30.9 | -2.27 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 6.37 | -36.1 | 112 | -92.7 | 24.1 |